Synaptogenix Inc (SNPX)

[SF Wolf]

This article is from Ray Dirk’s Blog 2&1/2 months ago. Amazingly, very little interest judging from the zero comments:

60 Minutes, Eli Lilly, Biogen, And Neurotrope, What A Story!
Nov. 30, 2016 2:51 PM ET

Some excertps:
“Dr. Alkon, currently President and Chief Scientific Officer of Neurotrope, (NTRP) was allowed under an FDA compassionate use program to treat the young lady. She was treated with a drug called bryostatin, which is not a statin, it activates PKC epsilon…

The activation of PKC epsilon activates the main amyloid degrading enzymes, ECE, neprilysin, and IDE while activating Alpha Secretase. Alpha Secretase has been a target for treating Alzheimer's. The problem has been finding a safe one. Eli Lilly's(LLY) and Biogen's (BIIB) drugs are monoclonal antibodies that inhibit amyloid beta. But Lilly's drug, solanezumab, just failed a major Phase III trial, showing it was no better at slowing down cognitive decline than placebo. Merck (MRK) has a BACE inhibitor that also inhibits amyloid beta. Neurotrope's bryostatin, in addition to degrading amyloid, also normalizes GSK3 beta. That mechanism prevents the hyperphosphorylation of tau. So you don't have to be a tauist or a baptist, bryostatin hits both targets.

Incredibly, bryostatin also activates growth factors in the brain, such as BDNF, NGF and IGF-1. This mechanism causes synaptogenesis. That allows the brain to restore damaged synapses and grow new synapses. The hope is that the damage caused by Alzheimer's disease may actually be reversed through this mechanism.

Dr. Alkon didn't start out by trying to find a drug to fight Alzheimer's. He was leading a department at the NIH trying to find out how to increase memory and he came upon PKC epsilon. PKC epsilon was the conductor in the center of the orchestra, arranging the different mechanisms to create the masterpiece of memory.”

http://seekingalpha.com/instablog/1240561-ray-dirks/4937731-60-minutes-eli-lilly-biogen-neurotrope-story